Pernix Therapeutics Announces Restructuring and Integration of the Pernix and Hawthorn Sales Forces

  Pernix Therapeutics Announces Restructuring and Integration of the Pernix
  and Hawthorn Sales Forces

Business Wire

THE WOODLANDS, Texas -- January 24, 2013

Pernix Therapeutics Holdings, Inc. (“Pernix” or the “Company”) (NYSE MKT:
PTX), a specialty pharmaceutical company, today announced that the Company has
initiated the integration of its Pernix and Hawthorn sales forces. The Company
has restructured the combined sales force, reducing the number of sales
representatives to approximately 125 from 187. The sales force will remain
focused on Pediatrics, Primary Care and Gastroenterology.

The Company today also announced that David Becker will resign his position as
Chief Financial Officer, due to personal reasons, effective March 31, 2013.
The Company has started a search to identify a new Chief Financial Officer.
Upon naming a successor, Mr. Becker will serve the Company as a consultant in
several areas, including manufacturing, over-the-counter products, and
business development.

Cooper Collins, President and CEO of Pernix, said, “We closed the acquisition
of Cypress and Hawthorn at the end of December, and we are rapidly making
progress in the implementation of our integration plans. In addition, we
appreciate the service that David has provided the Company, which included
building our OTC product group and completing several key business development
transactions that have broadened the scope of our business and expanded our
portfolio of branded and generic products.”

About Pernix Therapeutics Holdings, Inc.

Pernix Therapeutics is a specialty pharmaceutical company primarily focused on
the sales, marketing, manufacturing and development of branded, generic and
OTC pharmaceutical products. The Company manages a portfolio of branded
products, including the recently acquired Hawthorn Pharmaceuticals’ product
line. The Company’s branded products for the pediatrics market include CEDAX®,
an antibiotic for middle ear infections, NATROBA™, a topical treatment for
head lice marketed under an exclusive co-promotion agreement with ParaPRO,
LLC, and a family of treatments for cough and cold (ZUTRIPRO®, BROVEX®, ALDEX®
and PEDIATEX®). The Company’s branded products for gastroenterology include
OMECLAMOX-PAK®, a 10-day treatment for H. pylori infection and duodenal ulcer
disease, and REZYST™, a probiotic blend to promote dietary management. The
Company promotes its branded pediatric and gastroenterology products through
its sales force. Pernix markets its generic products through its wholly-owned
subsidiaries, Cypress Pharmaceuticals and Macoven Pharmaceuticals. The
Company’s wholly-owned subsidiary, Great Southern Laboratories, manufactures
and packages products for the pharmaceutical industry in a wide range of
dosage-forms. A product candidate utilizing cough-related intellectual
property is in development for the U.S. OTC market. Founded in 1996, the
Company is based in The Woodlands, TX.

Additional information about Pernix is available on the Company’s website
located at www.pernixtx.com.

Cautionary Notice Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. Statements including
words such as “estimate,” “plan,” “project,” “forecast,” “intend,” “expect,”
“anticipate,” “believe,” “seek,” “target” or similar expressions are
forward-looking statements. Because these statements reflect the Company’s
current views, expectations and beliefs concerning future events, these
forward-looking statements involve risks and uncertainties. No assurances can
be given regarding the Company’s future performance. Investors should note
that many factors, as more fully described under the caption "Risk Factors" in
our Form 10-K, Form 10-Q and Form 8-K filings with the Securities and Exchange
Commission and as otherwise enumerated herein or therein, could affect the
Company’s future financial results and could cause actual results to differ
materially from those expressed in forward-looking statements. The
forward-looking statements in this press release are qualified by these risk
factors. These are factors that, individually or in the aggregate, could cause
our actual results to differ materially from expected and historical results.
The Company assumes no obligation to publicly update any forward-looking
statements, whether as a result of new information, future developments or
otherwise.

Contact:

Pernix Therapeutics Holdings, Inc.
Joseph T. Schepers, (800) 793-2145 ext. 3002
Director, Investor Relations
jschepers@pernixtx.com
 
Press spacebar to pause and continue. Press esc to stop.